S. Rahsepar, Golnaz Abbasi Karizaki, Sara Samadi, Vahid Jomehzadeh, Seyed Alireza Sadjadi, Amirhosein Mohammadpour, O. Arasteh, T. Johnston, A. Sahebkar
{"title":"The Effects of Standard Pharmacotherapy on Oxidative Stress\nMarkers in Bipolar Patients: A Systematic Review","authors":"S. Rahsepar, Golnaz Abbasi Karizaki, Sara Samadi, Vahid Jomehzadeh, Seyed Alireza Sadjadi, Amirhosein Mohammadpour, O. Arasteh, T. Johnston, A. Sahebkar","doi":"10.2174/0126660822277544231207111352","DOIUrl":null,"url":null,"abstract":"\n\nBipolar disorder is a complex mental disorder with a multifactorial pathology. Meta-analyses have shown that bipolar disorder is associated with imbalanced oxidative status, which can contribute to disease progression. Therefore, restoring\nthe oxidative imbalance could be beneficial in the treatment of bipolar disorder. The firstline pharmacotherapy for bipolar disorder is lithium, anticonvulsants (particularly sodium\nvalproate), and atypical antipsychotics. In the present review, we sought to describe the\neffects of these first-line medications on oxidative stress in bipolar patients.\n\n\n\nWe systematically searched databases through January 2022, including the Web\nof Science, PubMed, Scopus, and Embase, with no language or time restrictions. Eligible\narticles that assessed oxidative markers in bipolar patients following standard pharmacotherapy were included.\n\n\n\nAccording to Newcastle Ottawa and NIH scales, the overall quality of the included\narticles was low, and their heterogeneity prevented us from performing a meta-analysis.\n\n\n\nWe found that standard medications, especially lithium, can potentially alleviate oxidative imbalance based on a reduction in oxidative markers, such as TBARs and\nMDA, although randomized clinical trials are needed to unequivocally confirm these results.\n","PeriodicalId":36711,"journal":{"name":"Current Psychiatry Research and Reviews","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Psychiatry Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0126660822277544231207111352","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Bipolar disorder is a complex mental disorder with a multifactorial pathology. Meta-analyses have shown that bipolar disorder is associated with imbalanced oxidative status, which can contribute to disease progression. Therefore, restoring
the oxidative imbalance could be beneficial in the treatment of bipolar disorder. The firstline pharmacotherapy for bipolar disorder is lithium, anticonvulsants (particularly sodium
valproate), and atypical antipsychotics. In the present review, we sought to describe the
effects of these first-line medications on oxidative stress in bipolar patients.
We systematically searched databases through January 2022, including the Web
of Science, PubMed, Scopus, and Embase, with no language or time restrictions. Eligible
articles that assessed oxidative markers in bipolar patients following standard pharmacotherapy were included.
According to Newcastle Ottawa and NIH scales, the overall quality of the included
articles was low, and their heterogeneity prevented us from performing a meta-analysis.
We found that standard medications, especially lithium, can potentially alleviate oxidative imbalance based on a reduction in oxidative markers, such as TBARs and
MDA, although randomized clinical trials are needed to unequivocally confirm these results.